Entrada Therapeutics, Inc. (TRDA)
| Market Cap | 172.35M -16.6% |
| Revenue (ttm) | 4.69M -94.1% |
| Net Income | -165.78M |
| EPS | -3.97 |
| Shares Out | 36.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 514,662 |
| Open | 4.520 |
| Previous Close | 4.550 |
| Day's Range | 4.425 - 4.960 |
| 52-Week Range | 4.109 - 16.450 |
| Beta | -0.24 |
| Analysts | Strong Buy |
| Price Target | 19.00 (+297.49%) |
| Est. Earnings | Nov 5, 2026 |
About TRDA
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was f... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for TRDA stock is "Strong Buy." The 12-month stock price target is $19.0, which is an increase of 297.49% from the latest price.
News
Entrada Therapeutics reports data from Cohort 1 of ELEVATE-45-201 clinical study
Entrada Therapeutics (TRDA) announced topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose, or MAD, portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENT...
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLO...
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non...
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 20...
Entrada Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The EEV platform enables superior delivery and safety for oligonucleotide therapies, with clinical programs in DMD showing early functional benefits and strong safety. Upcoming data from higher-dose cohorts and expansion studies aim to confirm dose-dependent efficacy and support accelerated approval, while a robust financial position and a strategic Vertex partnership underpin future growth.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purc...
Entrada Therapeutics price target raised to $11 from $10 at Roth Capital
Roth Capital raised the firm’s price target on Entrada Therapeutics (TRDA) to $11 from $10 and keeps a Buy rating on the shares after the company reported Q2 earnings and…
Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04)
Reports Q2 revenue $898,000, consensus $2.23M. “With multiple data readouts ahead in 2026, we are well positioned to deliver on important clinical milestones and further demonstrate the potential of o...
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVA...
Entrada Therapeutics Earnings release: Q2 2026
Entrada Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Entrada Therapeutics Quarterly report: Q2 2026
Entrada Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Entrada Therapeutics Slides: Corporate presentation
Entrada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Entrada Therapeutics Transcript: AGM 2026
The meeting covered board introductions, voting on four key proposals, and confirmation of a quorum. All proposals, including director elections and plan amendments, were approved by stockholders, with no questions raised during the session.
Entrada Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Entrada's EEV platform shows strong safety and early functional benefit in DMD, with higher dystrophin levels expected in upcoming cohorts. The pipeline includes DM1 (with Vertex) and inherited retinal diseases, with robust preclinical data and a solid cash runway into 2027.
Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim
Guggenheim lowered the firm’s price target on Entrada Therapeutics (TRDA) to $17 from $20 and keeps a Buy rating on the shares. A clean safety profile will be needed to…
Entrada Therapeutics Slides: Corporate presentation
Entrada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a deep, differentiated pipeline with five clinical programs, highlighted by strong safety and early functional efficacy in DMD trials. Multiple data catalysts are expected in 2026, supported by robust financials and strategic partnerships, including Vertex.
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GL...
Entrada Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The conference highlighted a novel EEV platform enabling efficient drug delivery and a DMD program showing strong safety and early functional benefit signals. Ongoing trials are escalating doses to optimize efficacy, with multiple data readouts and new ophthalmology candidates expected in 2024–2025.
Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Entrada Therapeutics, Inc. (NASDAQ: TRDA). The investigation focuses on Ent...
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $10 from $19 and keeps a Buy rating on the shares. The Phase 1/2 study Cohort 1 results…
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju downgraded Entrada Therapeutics (TRDA) to Neutral from Buy without a price target saying the ELEVATE-44-201 initial cohort data “underwhelm.” The functional ...
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
Entrada Therapeutics (TRDA) announced topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study. ELEVATE-44-201...
Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
Reports Q1 revenue $875,000, consensus $2.92M. “With the recently announced positive data from Cohort 1 of our ELEVATE-44-201 clinical study, this year has already delivered a significant clinical inf...
Entrada Therapeutics Transcript: Study result
Cohort 1 of the ELEVATE-44-201 study showed ENTR-601-44 was safe and led to significant functional improvement in DMD patients, despite lower than expected dystrophin levels. Higher doses in upcoming cohorts are expected to further increase dystrophin and functional benefit.